Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Sickle Cell Anemia Clinical Trial

Official title:

Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00040469
• Other study ID #: H6847
• Secondary ID: Scallo2
• Status: Terminated
• Phase: Phase 2
• Start date: August 2000
• Est. completion date: November 21, 2003

Study information

• Verified date: January 2020
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

Description:

To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe thalassemia or sickle cell disease.

We will do this by using three drugs: busulfan, cyclophosphamide, and CAMPATH-1H. CAMPATH-IH is an investigational drug. CAMPATH-1H is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body. After the drug treatment, participants will be given bone marrow from a brother or sister who has healthy bone marrow that matches.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 15
• Est. completion date: November 21, 2003
• Est. primary completion date: November 21, 2003
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 64 Years

Eligibility

Inclusion:

• Patients with homozygous B0/+ thalassemia or severe variants of B0/+ thalassemia with an HLA genotypically identical donor.

• Patients with an HLA genotype identical donor and hemoglobin SS, hemoglobin SC, or hemoglobin Sb 0/+ and at least one of the following:

Previous central nervous system vaso-occlusive episode with or without residual neurologic findings; Frequent painful vaso-occlusive episodes which significantly interfere with normal life activities and which necessitate chronic transfusion therapy; Recurrent SCD chest syndrome events which necessitate chronic transfusion therapy.

• Severe anemia which prevents acceptable quality of life and necessitates chronic transfusion therapy.

• The patient must have an HLA genotype identical donor.

• Between the ages of birth and 65 years.

• Women of childbearing potential must have a negative pregnancy test.

Exclusion:

• Biopsy proven chronic active hepatitis or fibrosis with portal bridging.

• SCD chronic lung disease >/= stage 3.

• Severe renal dysfunction defined as creatinine clearance <40 ml/min/1.73 M2

• Severe cardiac dysfunction defined as shortening fraction <25%.

• HIV infection.

• Severe but unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate bone marrow transplant (BMT).

• Inadequate intellectual capacity to understand the nature and risk inherent in the BMT process and give informed consent (in the case of minors, this criteria must be fulfilled by the legal guardian).

• Pregnant, lactating or unwilling to use appropriate birth control.

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Hemoglobinopathies
• Hemoglobinopathy
• Sickle Cell Anemia
• Thalassemia

Intervention

Drug:
• Campath -1H

• Dilantin

• Busulfan

• Cyclophosphamide

Locations

Country	Name	City	State
United States	Texas Children's Hospital	Houston	Texas
United States	The Methodist Hospital	Houston	Texas

Sponsors (3)

Lead Sponsor	Collaborator
Baylor College of Medicine	Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital System

Country where clinical trial is conducted

United States,